| HOME >> BIOLOGY >> TECHNOLOGY |
expanded the scope of compounds eligible for higher tier royalties
under the agreement.
-- PDE4 Inhibitor Program. The Company's PDE4 inhibitor program
includes MEM 1414, along with MEM 1917 and several backup compounds.
The Company believes that PDE4 inhibitors could be beneficial in
treating a number of cognition-related CNS disorders and
inflammatory diseases. MEM 1414 has demonstrated efficacy in a
broad range of preclinical cognition and anti-inflammatory models.
In addition, Phase 1 studies have demonstrated a favorable safety
profile for the compound overall and particularly with respect to
nausea and vomiting, which has limited the development of other PDE4
compounds. The Company plans to progress MEM 1414 into a Phase 2a
trial by the end of 2008.
-- 5-HT6 Antagonist Program. 5-HT6 antagonists are potential
treatments for Alzheimer's disease, schizophrenia, attention deficit
disorder and obesity. Memory Pharmaceuticals has generated a
portfolio of novel, potent and selective 5-HT6 antagonists and is
evaluating several lead compounds as potential development
candidates. The Company plans to advance the program into clinical
trials by the end of 2008.
Conference Call and Webcast Information
Memory Pharmaceuticals will hold a conference call today, March 12,
2008, at 9:00 a.m. EDT to discuss the new operational focus. The conference
call will also be broadcast live from the "Investors" section of the
Company's website. Memory Pharmaceuticals' senior management will host the
conference call. Investors and other interested parties may access the call
as follows:
Date: Wednesday, March 12, 2008
Time: 9:00 a.m. EDT
| SOURCE Memory Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved |